排序方式: 共有35条查询结果,搜索用时 0 毫秒
31.
Tomoteru Yamasaki Masayuki Fujinaga Yoko Shimoda Wakana Mori Yiding Zhang Hidekatsu Wakizaka Masanao Ogawa Ming-Rong Zhang 《Bioorganic & medicinal chemistry letters》2017,27(17):4114-4117
Cannabinoid receptor type 1 (CB1) is mainly expressed in the brain, as well as being expressed in functional relevant concentrations in various peripheral tissues. 1-(4-Chlorophenyl)-3-(3-(6-(pyrrolidin-1-yl)pyridin-2-yl)phenyl)urea (PSNCBAM-1, 1) was developed as a potent allosteric antagonist for CB1 and its oral administration led to reductions in the appetite and body weight of rats. Several analogs of 1 (compounds 2 and 3) were recently identified through a series of structure-activity relationship studies. Herein, we report the synthesis of radiolabeled analogs of these compounds using [11C]COCl2 and an evaluation of their potential as PET ligands for CB1 imaging using in vitro and in vivo techniques. [11C]2 and [11C]3 were successfully synthesized in two steps using [11C]COCl2. The radiochemical yields of [11C]2 and [11C]3 were 17 ± 8% and 20 ± 9% (decay-corrected to the end of bombardment, based on [11C]CO2). The specific activities of [11C]2 and [11C]3 were 42 ± 36 and 37 ± 13 GBq/μmol, respectively. The results of an in vitro binding assay using brown adipose tissue (BAT) homogenate showed that the binding affinity of 2 for CB1 (KD = 15.3 µM) was much higher than that of 3 (KD = 26.0 µM). PET studies with [11C]2 showed a high uptake of radioactivity in BAT, which decreased in animals pretreated with AM281 (a selective antagonist for CB1). In conclusion, [11C]2 may be a useful PET ligand for imaging peripheral CB1 in BAT. 相似文献
32.
Fresh isolates of Actinobacillus actinomycetemcomitans produce bundle-forming fimbriae. The exact molecular mass of A. actinomycetemcomitans fimbrillin, a structural subunit of fimbriae, was determined by liquid chromatography-electrospray ionization mass spectrometry. Three major molecular species with 6,226.0, 6,366.0, and 6,513.0 Da were detected in a purified fimbrial fraction from the strain 310-a. These molecular masses were significantly higher than the molecular weight (5,118 Da) calculated from nucleotide sequence data of the fimbrillin gene, flp, suggesting that the fimbrial peptides were post-translationally modified. Modification of the fimbrial peptides was also suggested by an N-terminal amino acid sequence analysis of fimbrillin peptic fragments, with the modified amino acids being due to seven serine or asparagine residues located in the C-terminal region. A periodate oxidation/biotin-hydrazide labeling assay of fimbrillin suggested that it might be glycosylated. 相似文献
33.
Masayuki Fujinaga Katsushi Kumata Kazuhiko Yanamoto Kazunori Kawamura Tomoteru Yamasaki Joji Yui Akiko Hatori Masanao Ogawa Yuichiro Yoshida Nobuki Nengaki Jun Maeda Ming-Rong Zhang 《Bioorganic & medicinal chemistry letters》2010,20(5):1565-1568
Two novel triaryl ligands 2 and 5 with potent in vitro binding affinities for the cannabinoid subtype-2 (CB2) receptor were labeled with a positron-emitting radioactive nuclide 11C. Radioligands [11C]2, [11C]5, and their analogs [11C]3 and [11C]4 were synthesized by O-[11C]methylation of their corresponding phenol precursors with [11C]CH3I. [11C]2–5 had relatively high uptakes (>1.2% injected dose/g tissue) in mouse brains. 相似文献
34.
Manabu Kuroki Ryusei Shingaki Yongming Qu 《Biometrical journal. Biometrische Zeitschrift》2021,63(1):105-121
One of the central aims in randomized clinical trials is to find well‐validated surrogate endpoints to reduce the sample size and/or duration of trials. Clinical researchers and practitioners have proposed various surrogacy measures for assessing candidate surrogate endpoints. However, most existing surrogacy measures have the following shortcomings: (i) they often fall outside the range [0,1], (ii) they are imprecisely estimated, and (iii) they ignore the interaction associations between a treatment and candidate surrogate endpoints in the evaluation of the surrogacy level. To overcome these difficulties, we propose a new surrogacy measure, the proportion of treatment effect mediated by candidate surrogate endpoints (PMS), based on the decomposition of the treatment effect into direct, indirect, and interaction associations mediated by candidate surrogate endpoints. In addition, we validate the advantages of PMS through Monte Carlo simulations and the application to empirical data from ORIENT (the Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial). 相似文献
35.
W. Ewan Hume Tomotaka Shingaki Tadayuki Takashima Yoshinobu Hashizume Takashi Okauchi Yumiko Katayama Emi Hayashinaka Yasuhiro Wada Hiroyuki Kusuhara Yuichi Sugiyama Yasuyoshi Watanabe 《Bioorganic & medicinal chemistry》2013,21(24):7584-7590
In order to develop a new positron emission tomography (PET) probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1), 11C-labelled metformin was synthesized and then evaluated as a PET probe. [11C]Metformin ([11C]4) was synthesized in three steps, from [11C]methyl iodide. Evaluation by small animal PET of [11C]4 showed that there was increased concentrations of [11C]4 in the livers of mice pre-treated with pyrimethamine, a potential inhibitor of MATEs, inhibiting the hepatobiliary excretion of metformin. Radiometabolite analysis showed that [11C]4 was not degraded in vivo during the PET scan. Biodistribution studies were undertaken and the organ distributions were extrapolated into a standard human model. In conclusion, [11C]4 may be useful as a PET probe to non-invasively study the in vivo function of hepatobiliary transport and drug–drug interactions, mediated by MATE1 in future clinical investigations. 相似文献